Microbicides 2004 Microbicides 200428-31 March 2004, Hilton London MetropoleThe conference42 million men, women and children worldwide were living with HIV by the end of December 2002 (source: UNAIDS), including five million newly-infected during that year alone. Another 45 million people will become infected between 2002 and 2010, unless the current transmission rates can be vastly reduced. Of the 42 million, 29.4 million live in sub-Saharan Africa and 58% of them are women. Not only are women more susceptible to HIV infection, many are powerless to insist on the use of condoms or other methods of protecting themselves. In this context, and with the knowledge that an effective HIV vaccine is unlikely to be available for several years, the need for an effective topical microbicide grows ever more urgent. 2004 should prove to be a landmark year in the field of microbicide development as the first Phase III trials of novel products are due to start – the next step along the road to making a microbicide available to the millions worldwide in desperate need of protection.The aims of the Microbicides 2004 conference are to:Report novel or innovative work in the microbicides fieldProvide updates on recent microbicides research, divided into three tracks: basic science, clinical science, and behavioural science (including public health and the microbicide marketplace)Provide a forum for the discussion of new developments in microbicide research including ethical, clinical, behavioural and methodological issuesPresent opportunities for knowledge-sharing between microbicide researchers, public-health workers and advocacy organisations.There will be an opening ceremony on the evening of Sunday 28 March at which politicians, policy makers and the international media are expected. The conference will run for a full three days, each of which will contain:Scientific overviews and presentations with plenary sessions, invited lecturers and presentations of original researchWorkshops to review issues unique to microbicides such as trial design and outcome measures, and ethical issues in the clinical trials of microbicidesPoster sessions. Focus on LondonFollowing the successful Microbicides conferences in Washington in 2000 and Antwerp in 2002, March 2004 sees the focus move to London.The venue is the Hilton Metropole Hotel, two minutes by taxi from Paddington station and the Heathrow Express, with a journey time from the airport of 15 minutes. The hotel is in walking distance of Hyde Park and London’s main shopping streets, and close to Imperial College. Accommodation will be available at the venue and other hotels in the vicinity.London in March offers a variety of diversions for out-of-conference relaxation, including sight-seeing and shopping; the arts and the theatre; and pubs, clubs and restaurants to suit every taste. Conference staff will be on hand to help delegates plan their spare time.To book your place or find out more information, e-mail info@microbicides2004.org.uk or telephone the Event Office on +44 (0) 20 7720 4411
Oral: invited speaker Oral: Track A Oral: Track B Oral: Track C Poster: Track A Poster: Track B Poster: Track C Abstract only Authors

02225 ANTI-HIV AND OTHER STD PATHOGEN ACTIVITIES OF A COMBINATIONAL MICROBICIDE CANDIDATE, PL40

Yang, Jing1, 2
Liang Z1,3 Chen C2, Wang X3, Ben K1.
1 Kunming Chinawave Biotechnology Co Ltd, Kunming 650106, China; 2 Kunming University of Science and Technology, Kunming 650224, China; 3 Yunnan Normal University, Kunming 650092, China

Combinational microbicide targets at two or more sites in fighting against HIV-1 infection and is expected to be more powerful than single compound. We designed a combinational microbicide candidate, PL40, which is composed of PS20 and LN43. PS20 with high anti-HIV activity is a plant-derived polysaccharide sulfate, and was reported in the last conference (A017). LN43 is a rare earth compound with small molecular weight. The anti-HIV activity of LN43 was detected by syncytial formation inhibition assay for HIV?B and by p24 ELISA assay for R5 strain (HIVAda-M), and its effective concentration (EC50) was 23.0 mg/ml and 23.8 mg/ml, and its therapeutic index?TI?was 97 and 76, respectively. EC50 of PS20 in anti-HSV activity detected by plaque reduction assay was 68 mg/ml. The minimum inhibition concentration (MIC) of LN43 defined as &Mac179; 90? inhibition compared to growth control was 1.17 mg/ml for Candida albicans using an improved MTT test. Both compounds had no inhibition activity for either Neisseria gonorrhoeae or Ureaplasma urealyticum. The time-of-addition experiment showed that both compounds may target at early stage (binding/fusion) of HIV-1 replicate cycle. Furthermore, when combined usage of PS20 with LN43 at concentration ratios of 1:1, 1:4 and 1:11 and at ECs50, 70 and 90, their means of anti-HIV-1 combination indeces (CIs) measured using mixed dose effect analyses and the CalcuSyn package were less than 0.5, and the strong synergism was shown.

Postgraduate student, Jing Yang
Kunming Chinawave Biotechnology Co. Ltd, 53 Keyi Road, Kunming, Yunnan 650106, China
(Telephone) 0086-0871-831-7372 (Fax) 0086-0871-831-7372 (E-mail) kmyangjing@sina.com.cn